Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1B | P36896 | 1/20 | 0.46 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 5/20 | 0.44 |
| ▸ | ABL1 | P00519 | 6/20 | 0.41 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.38 |
| ▸ | GCK | P35557 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1844572 | 0.88 | ABL1 (0.45) | ABL1KDR | |
| SCHEMBL1842825 | 0.84 | ABL1 (0.44) | ABL1 | |
| SCHEMBL1841832 | 0.83 | ACVR1B (0.45) | ACVR1BTGFBR1ATMCHEK2 | |
| SCHEMBL1842433 | 0.83 | ABL1 (0.42) | ABL1 | |
| SCHEMBL1842847 | 0.82 | ABL1 (0.43) | ABL1 | |
| Lithium SCHEMBL1842854 | 0.82 | ABL1 (0.43) | ABL1 | |
| SCHEMBL1841588 | 0.81 | — | — | |
| SCHEMBL1841659 | 0.81 | NPC1 (0.43) | ABL1 | |
| Lithium Ion SCHEMBL1842848 | 0.81 | ABL1 (0.40) | ABL1 | |
| SCHEMBL1840902 | 0.81 | NPC1 (0.41) | ABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110166088-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2011-07-07 | — | — | US | claimed |
| US-20110166088-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2011-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110166088-A1 | BENZOTHIAZOLES AND AZA-ANALOGUES THEREOF USE AS ANTIBACTERIAL AGENTS | TOP2B, TOP1, POLI | ACVR1B 4206/4885TGFBR1 3737/4885ATM 895/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.